Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Microbix Biosystms, with a price target of C$0.40.

David Martin PhD has given his Buy rating due to a combination of factors that point to Microbix’s underlying strength despite a weak quarter. He notes that the revenue shortfall was largely driven by a temporary pullback in Chinese antigen orders following an unusually light respiratory season, rather than by structural issues in the business, and that demand from non‑Chinese customers is already growing again, signaling a healthier baseline.

At the same time, he highlights that Microbix has diversified its revenue base beyond China and is demonstrating sequential growth in other markets, which should reduce future volatility. In his view, this positioning, combined with the prospect of sales normalization as inventories are worked down and the stock’s current valuation, offers an attractive risk‑reward profile that justifies a Buy recommendation.